Areas of Investigation

We are actively conducting research in the following diseases:

Graft versus Host Disease (GvHD)

Mallinckrodt is actively engaged in an ongoing clinical trial to assess the efficacy of THERAKOS ECP Immunomodulation™ in steroid-refractory acute GvHD in paediatric patients.

More information about this study is available at:


Reference: UVADEX™ 20 micrograms/ml solution for blood fraction modification [Professional Leaflet]. 

Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.


© 2018 Mallinckrodt. Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at Damastown, Mulhuddart, Dublin 15, Ireland.